Phase 2a study of ZGN-1061 in patients with type 2 diabetes who are overweight or obese

Trial Profile

Phase 2a study of ZGN-1061 in patients with type 2 diabetes who are overweight or obese

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs ZGN 1061 (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Aug 2017 According to a Zafgen media release, this trial is expected to begin in the third quarter of 2017.
    • 09 May 2017 According to a Zafgen media release, data from this trial expected by the end of 2018.
    • 09 May 2017 According to a Zafgen media release, based on the data from a Phase I trial (see profile 274521) along with non-clinical data supporting a differentiated profile and improved safety margin versus first generation MetAP2 inhibitors, the Company plans to initiate this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top